Loss of ≥ 15 letters BCVA at 1 year · proliferative diabetic retinopathy
0.5 may leads to lower BCVA: loss of 15 or more EDTRS letters ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
BCVA: gain of 15 or more ETDRS letters · proliferative diabetic retinopathy
0.5 showed no clear difference in BCVA: gain of 15 or more EDTRS letters ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
Progression of PDR · proliferative diabetic retinopathy
It is very uncertain whether 0.5 changes progression of PDR ‐ 1 year compared with 0.1 second exposure (very low certainty).
1 finding from 1 review
Regression of PDR · proliferative diabetic retinopathy
0.5 showed no clear difference in regression of PDR ‐ 1 year compared with 0.1 second exposure (low certainty).
1 finding from 1 review
Pain during laser treatment ‐ not reported · proliferative diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · proliferative diabetic retinopathy
1 finding from 1 review
Eyes within ± 0.5 D of target refraction · adults (18 years) with more than 0.5 diopters of myopia or myopic astigmatism
Laser‐assisted in‐situ keratomileusis (LASIK) with a mechanical… showed no clear difference in proportion of eyes within ± 0.5 diopters of target refraction, 12… compared with LASIK with a femtosecond laser (low certainty).
1 finding from 1 review
Outcomes at 24 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from disability worsening compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).
1 finding from 1 review
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in participants free from disability worsening compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Pruritus · children with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found